\-\ Texto\\:\\ \ \(0\)\
\-\ none\ \(204\)\
\-\ orchiectomy\ \(25\)\
\-\ sonographic\\ longitudinal\\ images\\ of\\ the\\ left\\ testis\\ \\ demonstrates\\ a\\ hypoechoic\\ 4mm\\ nodule\\.\\ additionally\\,\\ several\\ \\(less\\ than\\ 5\\)\\ punctate\\ hyperechoic\\ foci\\ are\\ present\\ consistent\\ with\\ limited\\ microlithiasis\\.\ \(0\)\
\-\ testicular\\ microlithiasis\ \(11\)\
\-\ testicular\\ seminoma\ \(2\)\
\-\ nodule\\:\ \(1\)\
\-\ 1\\.\\ testicular\\ neoplasm\ \(0\)\
\-\ 2\\.\\ hematoma\ \(0\)\
\-\ 3\\.\\ trauma\\ \ \(0\)\
\-\ 4\\.\\ infection\ \(0\)\
\-\ punctate\\ hyperechoic\\ foci\\:\\ limited\\ microlithiasis\\ \ \(0\)\
\-\ causes\\:\ \(5\)\
\-\ 1\\.\\ granulomatous\\ changes\ \(2\)\
\-\ 2\\.\\ scar\ \(2\)\
\-\ 3\\.\\ benign\\ adenomatoid\\ tumor\ \(2\)\
\-\ 4\\.\\ hemorrhage\ \(2\)\
\-\ 5\\.\\ post\\-inflammatory\\ changes\ \(2\)\
\-\ 27\\ year\\ old\\ man\\ status\\ post\\ trauma\\ with\\ pain\\ in\\ testicles\\.\\ ultrasound\\ requested\\ to\\ evaluate\\ source\\ of\\ pain\\ and\\ possible\\ trauma\\.\ \(0\)\
\-\ classic\\ testicular\\ microlithiasis\\ is\\ defined\\ as\\ greater\\ than\\ 5\\ hyperechoic\\ nonshadowing\\ foci\\ \\(in\\ one\\ image\\)\\ throughout\\ the\\ parenchyma\\ of\\ the\\ testes\\.\\ although\\ frequently\\ symmetric\\,\\ it\\ can\\ often\\ times\\ be\\ asymptomatic\\ and\\ seen\\ on\\ the\\ periphery\\ of\\ the\\ testis\\.\\ in\\ patients\\ where\\ less\\ than\\ 5\\ foci\\ are\\ present\\ per\\ image\\,\\ limited\\ microlithiasis\\ is\\ diagnosed\\.\\ \ \(0\)\
\-\ previously\\ it\\ was\\ thought\\ that\\ germ\\ cell\\ tumors\\ were\\ present\\ in\\ up\\ to\\ 40\\%\\ of\\ patients\\ with\\ microlithiasis\\ \\(ref\\ 1\\ and\\ 2\\)\\.\\ this\\ corresponded\\ to\\ approximately\\ 21\\ times\\ increased\\ risk\\ of\\ testicular\\ cancer\\.\\ due\\ to\\ these\\ limited\\ studies\\,\\ there\\ were\\ controversial\\ recommendations\\ to\\ perform\\ yearly\\ ultrasound\\ follow\\-up\\ examinations\\ in\\ these\\ patients\\.\\ these\\ studies\\ were\\ performed\\ with\\ small\\ patient\\ numbers\\ in\\ individuals\\ referred\\ for\\ ultrasound\\ due\\ to\\ identification\\ of\\ testicular\\ masses\\.\ \(0\)\
\-\ more\\ recent\\ studies\\ \\(ref\\ 3\\ and\\ 4\\)\\ were\\ performed\\ with\\ much\\ larger\\ study\\ subjects\\ involving\\ all\\ patients\\ undergoing\\ testicular\\ ultrasound\\ for\\ any\\ reason\\.\\ they\\ have\\ demonstrated\\ less\\ risk\\ \\(8\\%\\)\\ of\\ testicular\\ neoplasms\\ in\\ patients\\ with\\ microlithiasis\\ than\\ previously\\ thought\\.\\ moreover\\,\\ with\\ an\\ average\\ follow\\-up\\ ultrasound\\ average\\ of\\ 42\\ months\\,\\ no\\ additional\\ tumors\\ were\\ identified\\ in\\ these\\ patients\\ \\(ref\\ 4\\)\\.\\ the\\ authors\\ of\\ these\\ studies\\ suggested\\ that\\ it\\ would\\ not\\ significantly\\ affect\\ mortality\\/morbidity\\ to\\ continue\\ annual\\ ultrasound\\ surveillance\\.\\ they\\ suggested\\ a\\ more\\ reasonable\\ approach\\ to\\ patients\\ with\\ limited\\/classic\\ microlithiasis\\ would\\ be\\ to\\ perform\\ annual\\ physical\\ exams\\ and\\ montly\\ self\\-exams\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ backus\\,\\ et\\.al\\.\\,\\ radiology\\ 1994\\;\\ 192\\:781\\-785\\.\\ \\(42\\ patients\\)\ \(0\)\
\-\ 2\\.\\ miller\\,\\ et\\.al\\.\\,\\ j\\ clin\\ ultrasound\\ 1996\\;\\ 24\\:197\\-202\\.\ \(0\)\
\-\ 3\\.\\ bennett\\,\\ et\\ al\\.\\,\\ testicular\\ microlithiasis\\:\\ us\\ follow\\-up\ \(0\)\
\-\ radiology\\.\\ 2001\\;218\\:359\\-363\\.\\ \ \(0\)\
\-\ 4\\.\\ middleton\\,\\ et\\ al\\.\\,testicular\\ microlithiasis\\:\\ prospective\\ analysis\\ of\\ prevalence\\ and\\ associated\\ tumor\ \(0\)\
\-\ radiology\\ 2002\\;224\\:425\\-428\\.\\ \\(1079\\ patients\\,\\ 195\\ with\\ testicular\\ microlithiasis\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ microlithiasis\\:\\ 0\\.16072284797011283\ \(0\)\
\-\ testicular\\:\\ 0\\.11538688487166274\ \(0\)\
\-\ patients\\:\\ 0\\.04761763491457951\ \(0\)\
\-\ ref\\:\\ 0\\.04337030886406735\ \(0\)\
\-\ ultrasound\\:\\ 0\\.04245420596900508\ \(0\)\
\-\ et\\.al\\.\\:\\ 0\\.03692299586267171\ \(0\)\
\-\ foci\\:\\ 0\\.0351007076282588\ \(0\)\
\-\ limited\\:\\ 0\\.03450748584808686\ \(0\)\
\-\ hyperechoic\\:\\ 0\\.030661892165285847\ \(0\)\
\-\ studies\\:\\ 0\\.03054067863903502\ \(0\)\
\-\ al\\.\\:\\ 0\\.02922233599456597\ \(0\)\
\-\ these\\:\\ 0\\.02660101306169665\ \(0\)\
\-\ radiology\\:\\ 0\\.02591994069538064\ \(0\)\
\-\ testis\\:\\ 0\\.02490239479101566\ \(0\)\
\-\ 4\\.\\:\\ 0\\.02414698543349855\ \(0\)\
\-\ punctate\\:\\ 0\\.02386065563386317\ \(0\)\
\-\ average\\:\\ 0\\.02386065563386317\ \(0\)\
\-\ perform\\:\\ 0\\.023461700567169147\ \(0\)\
\-\ were\\:\\ 0\\.02320916670681724\ \(0\)\
\-\ than\\:\\ 0\\.021426304831753815\ \(0\)\
\-\ 3\\.\\:\\ 0\\.020984743149335364\ \(0\)\
\-\ suggested\\:\\ 0\\.020811532561301027\ \(0\)\
\-\ less\\:\\ 0\\.020769904337244134\ \(0\)\
\-\ 42\\:\\ 0\\.020702784948489754\ \(0\)\
\-\ annual\\:\\ 0\\.020492435075661446\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.019952418598864177\ \(0\)\
\-\ times\\:\\ 0\\.01982148128949565\ \(0\)\
\-\ 2\\.\\:\\ 0\\.019503187620576016\ \(0\)\
\-\ mortality\\/morbidity\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ limited\\/classic\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ backus\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ 192\\:781\\-785\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ 24\\:197\\-202\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ 218\\:359\\-363\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ 224\\:425\\-428\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ 1079\\:\\ 0\\.019431510151690316\ \(0\)\
\-\ \\;\\:\\ 0\\.019382020942130082\ \(0\)\
\-\ 1\\.\\:\\ 0\\.019156860045198093\ \(0\)\
\-\ thought\\:\\ 0\\.018816825365455155\ \(0\)\
\-\ montly\\:\\ 0\\.018461497931335856\ \(0\)\
\-\ self\\-exams\\:\\ 0\\.018461497931335856\ \(0\)\
\-\ 5\\:\\ 0\\.017943735089312178\ \(0\)\
\-\ 195\\:\\ 0\\.017773263308245472\ \(0\)\
\-\ post\\-inflammatory\\:\\ 0\\.01723942706108229\ \(0\)\
\-\ subjects\\:\\ 0\\.01723942706108229\ \(0\)\
\-\ previously\\:\\ 0\\.017175941388771754\ \(0\)\
\-\ nodule\\:\\ 0\\.016852696647090937\ \(0\)\
\-\ nonshadowing\\:\\ 0\\.016803251087891012\ \(0\)\
\-\ trauma\\:\\ 0\\.016772790299698057\ \(0\)\
\-\ et\\:\\ 0\\.016733963780489386\ \(0\)\
\-\ corresponded\\:\\ 0\\.01643446955720379\ \(0\)\
\-\ middleton\\:\\ 0\\.01643446955720379\ \(0\)\
\-\ \\:\\:\\ 0\\.01622404042091864\ \(0\)\
\-\ numbers\\:\\ 0\\.01583323886753655\ \(0\)\
\-\ bennett\\:\\ 0\\.01583323886753655\ \(0\)\
\-\ moreover\\:\\ 0\\.015581180217637445\ \(0\)\
\-\ tumors\\:\\ 0\\.015357494534308617\ \(0\)\
\-\ miller\\:\\ 0\\.015353165433416572\ \(0\)\
\-\ risk\\:\\ 0\\.014809601183536298\ \(0\)\
\-\ they\\:\\ 0\\.014731799648264623\ \(0\)\
\-\ would\\:\\ 0\\.01455008075800043\ \(0\)\
\-\ testicles\\:\\ 0\\.014045644604784828\ \(0\)\
\-\ present\\:\\ 0\\.013851737468409193\ \(0\)\
\-\ \\(\\:\\ 0\\.013825104808494937\ \(0\)\
\-\ yearly\\:\\ 0\\.013806210493404485\ \(0\)\
\-\ 1994\\:\\ 0\\.013806210493404485\ \(0\)\
\-\ it\\:\\ 0\\.01378599319042835\ \(0\)\
\-\ 4mm\\:\\ 0\\.013694918589971728\ \(0\)\
\-\ authors\\:\\ 0\\.013694918589971728\ \(0\)\
\-\ \\)\\:\\ 0\\.013656223772503447\ \(0\)\
\-\ recommendations\\:\\ 0\\.013588574660376431\ \(0\)\
\-\ reasonable\\:\\ 0\\.013486757401001321\ \(0\)\
\-\ prospective\\:\\ 0\\.013486757401001321\ \(0\)\
\-\ controversial\\:\\ 0\\.013389097127029419\ \(0\)\
\-\ orchiectomy\\:\\ 0\\.013295267669724917\ \(0\)\
\-\ adenomatoid\\:\\ 0\\.013295267669724917\ \(0\)\
\-\ identification\\:\\ 0\\.012874476601630028\ \(0\)\
\-\ reason\\:\\ 0\\.012874476601630028\ \(0\)\
\-\ testes\\:\\ 0\\.012798522777910935\ \(0\)\
\-\ 1996\\:\\ 0\\.012798522777910935\ \(0\)\
\-\ image\\:\\ 0\\.012771240030132061\ \(0\)\
\-\ seminoma\\:\\ 0\\.012724906369617267\ \(0\)\
\-\ surveillance\\:\\ 0\\.012724906369617267\ \(0\)\
\-\ examinations\\:\\ 0\\.01258413962315092\ \(0\)\
\-\ prevalence\\:\\ 0\\.01258413962315092\ \(0\)\
\-\ clin\\:\\ 0\\.012036671746526883\ \(0\)\
\-\ requested\\:\\ 0\\.011930327816931586\ \(0\)\
\-\ individuals\\:\\ 0\\.011930327816931586\ \(0\)\
\-\ affect\\:\\ 0\\.01177918211927242\ \(0\)\
\-\ changes\\:\\ 0\\.011717932900646223\ \(0\)\
\-\ exams\\:\\ 0\\.011546732960292402\ \(0\)\
\-\ periphery\\:\\ 0\\.01141738554098552\ \(0\)\
\-\ performed\\:\\ 0\\.011399896321661813\ \(0\)\
\-\ 4\\:\\ 0\\.01139221007262701\ \(0\)\
\-\ 2002\\:\\ 0\\.011177951429605181\ \(0\)\
\-\ continue\\:\\ 0\\.011030683743003667\ \(0\)\
\-\ due\\:\\ 0\\.010910416999774351\ \(0\)\
\-\ 2001\\:\\ 0\\.010858498337202016\ \(0\)\
\-\ source\\:\\ 0\\.010792950552062985\ \(0\)\
\-\ approach\\:\\ 0\\.010729150917895136\ \(0\)\
\-\ longitudinal\\:\\ 0\\.010697877995485201\ \(0\)\
\-\ scar\\:\\ 0\\.010667008605925614\ \(0\)\
\-\ germ\\:\\ 0\\.01057672073993794\ \(0\)\
\-\ significantly\\:\\ 0\\.010461404706880817\ \(0\)\
\-\ neoplasms\\:\\ 0\\.010405766280650514\ \(0\)\
\-\ analysis\\:\\ 0\\.010405766280650514\ \(0\)\
\-\ more\\:\\ 0\\.010225723968000795\ \(0\)\
\-\ undergoing\\:\\ 0\\.010025228733689537\ \(0\)\
\-\ sonographic\\:\\ 0\\.009910740644747826\ \(0\)\
\-\ granulomatous\\:\\ 0\\.009866436702720945\ \(0\)\
\-\ larger\\:\\ 0\\.009844588655918855\ \(0\)\
\-\ \\,\\:\\ 0\\.009714476035309356\ \(0\)\
\-\ \\%\\:\\ 0\\.009537421212181854\ \(0\)\
\-\ tumor\\:\\ 0\\.009532211969429718\ \(0\)\
\-\ 27\\:\\ 0\\.009482029091021246\ \(0\)\
\-\ much\\:\\ 0\\.009463411530155086\ \(0\)\
\-\ symmetric\\:\\ 0\\.009336994110599154\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.009319467698895629\ \(0\)\
\-\ 21\\:\\ 0\\.009250618501407487\ \(0\)\
\-\ j\\:\\ 0\\.009233711402787649\ \(0\)\
\-\ to\\:\\ 0\\.00919524635403559\ \(0\)\
\-\ per\\:\\ 0\\.008948192843858066\ \(0\)\
\-\ additionally\\:\\ 0\\.00886012113782286\ \(0\)\
\-\ frequently\\:\\ 0\\.00886012113782286\ \(0\)\
\-\ 5\\.\\:\\ 0\\.008817272031204365\ \(0\)\
\-\ parenchyma\\:\\ 0\\.008706623663618825\ \(0\)\
\-\ defined\\:\\ 0\\.008613834130041895\ \(0\)\
\-\ 40\\:\\ 0\\.008600867461454961\ \(0\)\
\-\ us\\:\\ 0\\.008575143079215098\ \(0\)\
\-\ references\\:\\ 0\\.008499589079094767\ \(0\)\
\-\ where\\:\\ 0\\.008343641758796452\ \(0\)\
\-\ evaluate\\:\\ 0\\.008263699182433188\ \(0\)\
\-\ additional\\:\\ 0\\.008197240895095687\ \(0\)\
\-\ in\\:\\ 0\\.008065018758665166\ \(0\)\
\-\ causes\\:\\ 0\\.007958327028253137\ \(0\)\
\-\ classic\\:\\ 0\\.007833145643081511\ \(0\)\
\-\ referred\\:\\ 0\\.007714190056113974\ \(0\)\
\-\ greater\\:\\ 0\\.007678747267154309\ \(0\)\
\-\ throughout\\:\\ 0\\.007652505565310829\ \(0\)\
\-\ 8\\:\\ 0\\.007643821909687436\ \(0\)\
\-\ diagnosed\\:\\ 0\\.007517213293767955\ \(0\)\
\-\ identified\\:\\ 0\\.007304945074608424\ \(0\)\
\-\ status\\:\\ 0\\.007297433782731228\ \(0\)\
\-\ hematoma\\:\\ 0\\.007275040379000215\ \(0\)\
\-\ involving\\:\\ 0\\.007173223119625104\ \(0\)\
\-\ that\\:\\ 0\\.007062108749085279\ \(0\)\
\-\ benign\\:\\ 0\\.007055144418739716\ \(0\)\
\-\ neoplasm\\:\\ 0\\.006962097071559636\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.006910508129177242\ \(0\)\
\-\ masses\\:\\ 0\\.006910508129177242\ \(0\)\
\-\ although\\:\\ 0\\.006904137034872257\ \(0\)\
\-\ possible\\:\\ 0\\.0068851249255599805\ \(0\)\
\-\ recent\\:\\ 0\\.006872533609664586\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.006804441588937884\ \(0\)\
\-\ study\\:\\ 0\\.006726390805885069\ \(0\)\
\-\ cancer\\:\\ 0\\.006720491063073601\ \(0\)\
\-\ several\\:\\ 0\\.006571992429957865\ \(0\)\
\-\ often\\:\\ 0\\.006522663991673809\ \(0\)\
\-\ post\\:\\ 0\\.006437404385340415\ \(0\)\
\-\ any\\:\\ 0\\.006437404385340415\ \(0\)\
\-\ approximately\\:\\ 0\\.00632492303003728\ \(0\)\
\-\ be\\:\\ 0\\.006305056092554684\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005998612398222409\ \(0\)\
\-\ infection\\:\\ 0\\.005942623382949299\ \(0\)\
\-\ all\\:\\ 0\\.005782113611079643\ \(0\)\
\-\ months\\:\\ 0\\.00558359161409107\ \(0\)\
\-\ are\\:\\ 0\\.005573559198706228\ \(0\)\
\-\ one\\:\\ 0\\.005540027232800584\ \(0\)\
\-\ cell\\:\\ 0\\.0055221069655059475\ \(0\)\
\-\ up\\:\\ 0\\.005497241988167998\ \(0\)\
\-\ none\\:\\ 0\\.005071099298822982\ \(0\)\
\-\ physical\\:\\ 0\\.00501556284588813\ \(0\)\
\-\ consistent\\:\\ 0\\.005012675284285175\ \(0\)\
\-\ increased\\:\\ 0\\.0050011597650709465\ \(0\)\
\-\ pain\\:\\ 0\\.004993340514501123\ \(0\)\
\-\ 1\\:\\ 0\\.004864417148228964\ \(0\)\
\-\ man\\:\\ 0\\.004834765174856457\ \(0\)\
\-\ associated\\:\\ 0\\.004824073114611727\ \(0\)\
\-\ 3\\:\\ 0\\.00478702279116397\ \(0\)\
\-\ small\\:\\ 0\\.004709510249715595\ \(0\)\
\-\ can\\:\\ 0\\.004636895580069545\ \(0\)\
\-\ demonstrates\\:\\ 0\\.004465600960892789\ \(0\)\
\-\ have\\:\\ 0\\.004426885354940411\ \(0\)\
\-\ 2\\:\\ 0\\.00440216386725011\ \(0\)\
\-\ seen\\:\\ 0\\.004039778983415527\ \(0\)\
\-\ images\\:\\ 0\\.003921683952031948\ \(0\)\
\-\ for\\:\\ 0\\.003488555735132608\ \(0\)\
\-\ as\\:\\ 0\\.0030922906839572434\ \(0\)\
\-\ of\\:\\ 0\\.003065889494683906\ \(0\)\
\-\ there\\:\\ 0\\.0030423817140310732\ \(0\)\
\-\ not\\:\\ 0\\.0029541116548850127\ \(0\)\
\-\ an\\:\\ 0\\.0028269494360878703\ \(0\)\
\-\ is\\:\\ 0\\.0026903864994484478\ \(0\)\
\-\ and\\:\\ 0\\.0025838613262997865\ \(0\)\
\-\ with\\:\\ 0\\.0025192286717918844\ \(0\)\
\-\ was\\:\\ 0\\.002364300292377241\ \(0\)\
\-\ this\\:\\ 0\\.0022993713237180217\ \(0\)\
\-\ left\\:\\ 0\\.0022873331800787435\ \(0\)\
\-\ year\\:\\ 0\\.0022873331800787435\ \(0\)\
\-\ old\\:\\ 0\\.002093144968569987\ \(0\)\
\-\ no\\:\\ 0\\.002058478829434933\ \(0\)\
\-\ patient\\:\\ 0\\.0020492629926229375\ \(0\)\
\-\ the\\:\\ 0\\.00198443949335348\ \(0\)\
\-\ a\\:\\ 0\\.0018976067072660346\ \(0\)\
\-\ \\.\\:\\ 0\\.0017834695168523248\ \(0\)\
\-\ on\\:\\ 0\\.001731796680300067\ \(0\)\
